| Methods | n = 227 Allocation concealment: not described Baseline similarity: APACHE II (D) Blinding: caregivers (sham medication delivery in control group) Cointerventions: not described (lung protective ventilation "encouraged") Withdrawals: not described Losses to follow‐up: treatment (1/118); control (1/109) |
|
| Participants | Patients with ARDS (not described) | |
| Interventions | Intratracheal synthetic surfactant (Venticute, containing 1 mg recombinant surfactant protein C and 50 mg phospholipids per ml), 1 ml/kg up to 4 doses in 12‐24 hours, or standard therapy | |
| Outcomes | 28 day mortality: RR 0.99 (95% CI 0.71 to 1.37), based on data from 225 patients Ventilator‐free days to day 28: "not different between the groups" (data not reported) |
|
| Notes | Data from Spragg 2002a (North American trial) and Spragg 2002b (European/South African trial) are presented in the same abstract. Neither trial has been published in full. | |
| Risk of bias | ||
| Bias | Authors' judgement | Support for judgement |
| Allocation concealment (selection bias) | Unclear risk | B ‐ Unclear |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.